Omalizumab for Chronic Urticaria: Aftermarket Reports of Efficacy and Side Effect

Abstract

Purpose of Review The purpose of this study was to review real-life studies on effectiveness and safety of omalizumab in chronic urticaria (CU). Recent Findings CU is an itching skin disease characterized by wheals, angioedema, or both (present >6 weeks). Omalizumab is a humanized anti-IgE monoclonal antibody approved for treatment of CU and is becoming one of the main treatment options for antihistamine-resistant CU; however, real-life studies on long-term effectiveness and safety are lacking. Summary We present an overview of the real-life literature totaling 505 patients with an age range of 7–82 years, on the effectiveness and safety of omalizumab used for CU since 2013. A complete response to omalizumab was seen among 64% of the patients, whereas 25% obtained partial response. On average, 15% had no or very limited response. Fifteen patients from five studies reported side effects. Overall, omalizumab was effective and well-tolerated for patients with antihistamine-resistant CU.
OriginalsprogEngelsk
TidsskriftCurrent Dermatology Reports
Vol/bind6
Sider (fra-til)48-54
Antal sider6
ISSN2162-4933
DOI
StatusUdgivet - 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Omalizumab for Chronic Urticaria: Aftermarket Reports of Efficacy and Side Effect'. Sammen danner de et unikt fingeraftryk.

Citationsformater